IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease.
As a partial fatty acid oxidation inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed, thereby increasing the efficiency of energy generation.
IMPROVE-HCM is a randomized, double-blind, placebo-controlled study that will assess the safety, tolerability, and efficacy of IMB-101 in patients with non-obstructive hypertrophic cardiomyopathy.
This study will measure the change from baseline of peak oxygen consumption and oxygen uptake efficiency slope, measured by standardized cardiopulmonary exercise testing in 60 non-obstructive HCM patients treated with 200 mg BID of IMB-101 over a 12-week period.
Incidence and severity of treatment emergent Adverse Events, as well as incidence of treatment emergent Serious Adverse Events will also be examined.
IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease.
As a partial fatty acid oxidation inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency.
IMB-101 is currently being investigated in three Phase 2 proof-of-concept studies in patients with hypertrophic cardiomyopathy, stable angina, and type 2 diabetes at risk for diabetic cardiomyopathy.
Imbria Pharmaceuticals uses a deep understanding of energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering diseases.
Its clinical stage pipeline is focused on restoring or improving the cell's ability to produce energy in disorders where energetic impairment is a fundamental contributor, including cardiovascular disease and specific inborn errors of metabolism.
The company's lead program, IMB-101, is currently in Phase 2 clinical development in three indications: Hypertrophic cardiomyopathy, stable angina, and type 2 diabetes at risk for diabetic cardiomyopathy.
Imbria's pipeline also includes IMB-203, designed to address the energy deficiency in patients with rare inborn errors of mitochondrial metabolism.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes